Overview

Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.

Status:
RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety and tolerability of RCS-21 in healthy volunteers. Participants will be asked to inhale a single or multiple doses of RCS-21 for a maximum of 7 days and their health status will be constantly monitored.
Phase:
PHASE1
Details
Lead Sponsor:
RNATICS GmbH
Collaborator:
LungenClinic Grosshansdorf
Treatments:
mycophenolic adenine dinucleotide
Saline Solution